A Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Oral ACH-0143422 after Single and Multiple-ascending Doses in Health Volunteers and Subjects With Chronic Hepatitis C Virus Genotype 1 Infection

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Oral ACH-0143422 after Single and Multiple-ascending Doses in Health Volunteers and Subjects With Chronic Hepatitis C Virus Genotype 1 Infection

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs ACH 3422 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept; Therapeutic Use
  • Sponsors Achillion Pharmaceuticals
  • Most Recent Events

    • 25 Apr 2015 According to an Achillion Pharmaceuticals media release, data from this study were presented at the at the 50th Annual Meeting of the European Association for the Study of the Liver (EASL) during The International Liver Congress 2015.
    • 08 Apr 2015 Planned number of patients changed from 112 to 157, according to Australian New Zealand Clinical Trials Registry.
    • 08 Apr 2015 According to an Achillion media release, interim results from this study will be presented at the 50th Annual Meeting of the European Association for the Study of the Liver (EASL) during The International Liver Congress 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top